Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro

F Pettersson, KW Colston and AG Dalgleish

Department of Oncology, Gastroenterology, Endocrinology and Metabolism, St George's Hospital Medical School, London SW17 0RE, UK

Summary Retinoids and vitamin D are known to exert important anti-tumour effects in a variety of cell types. In this study the effects of 9-cis-retinoic acid (9cRA) the vitamin D analogues EB1089 and CB1093 on three pancreatic adenocarcinoma cell lines were investigated. All compounds caused inhibition of in vitro growth but the vitamin D analogues were generally the more potent growth inhibitors. They were also more effective on their own than in combination with 9cRA. Growth arrest correlated with an increased proportion of cells in the G0/G1 phase. Apoptosis was induced in the three cell lines by 9cRA, whereas neither EB1089 nor CB1093 had this effect. Furthermore, addition of EB1089 or CB1093 together with 9cRA resulted in significantly reduced apoptosis. Our results show that retinoic acids as well as vitamin D analogues have inhibitory effects on pancreatic tumour cells but different and antagonistic mechanisms seem to be employed. © 2000 Cancer Research Campaign

Keywords: 9-cis-retinoic acid; vitamin D analogues; pancreatic cancer; growth inhibition; apoptosis
vitamin D compounds indicate that the story is more complex and antagonistic as well as synergistic or additive effects can be seen in different systems (discussed in Haussler et al, 1998).

In the present study, the inhibitory effects of ATRA, 9cRA and the vitamin D analogues EB1089 and CB1093 on the three pancreatic adenocarcinoma cell lines AsPc-1, BxPc-3 and T3M-4 were investigated. Our results demonstrate varying degrees of sensitivity to all compounds, as evidenced by inhibition of in vitro growth. However, we also show that the retinoids and the vitamin D analogues employ different inhibitory mechanisms, as 9cRA but neither EB1089 nor CB1093 induced apoptosis and the vitamin D compounds even blocked apoptosis induced by 9cRA in the pancreatic adenocarcinoma cells.

MATERIALS AND METHODS

Cell lines

Human pancreatic adenocarcinoma cell lines AsPc-1 (Chen et al, 1982), BxPc-3 (Tan et al, 1986) and T3M-4 (Okabe et al, 1983) were obtained from Prof. N Lemoine (ICRF, London) and the American Tissue Culture Collection. All cells were maintained in RPMI-1640 culture medium with 10% fetal calf serum (FCS), 2 mM L-glutamine and antibiotics at 37°C in a humidified atmosphere containing 5% carbon dioxide. For growth inhibition and apoptosis studies cells were grown in medium containing 2.5% FCS. All cells were routinely tested for mycoplasma contamination.

Compounds

ATRA and 9cRA were purchased from Sigma (Poole, UK). EB1089 and CB1093 were provided by Leo Pharmaceutical Products (Ballerup, Denmark). The compounds were dissolved in ethanol and stored in the dark at –20°C. Dilutions were made up in complete culture medium with 10% fetal calf serum (FCS). 2 mM L-glutamine and antibiotics at 37°C in a humidified atmosphere containing 5% carbon dioxide. For growth inhibition and apoptosis studies cells were grown in medium containing 2.5% FCS. All cells were routinely tested for mycoplasma contamination.

Growth inhibition assays

Total cell numbers were assessed using the aminoxanthene dye sulphorhodamine B (SRB). SRB binds to basic amino acid residues in the cells and gives an index of culture cell protein that is linear with cell number (Skehan et al, 1990). Cells were plated in 48-well plates at a density of 2 × 10⁴ cells per well. After 24–48 h normal culture medium was exchanged for medium containing 2.5% serum and the inhibitory compounds. Control cells received 0.1% ethanol and fresh medium was added every 2–3 days. At the end of each experiment cells were fixed in 10% trichloroacetic acid (TCA) and stained with SRB. Bound SRB was solubilized in unbuffered 10 mM Tris, 50 μl aliquots were transferred to 96-well plates and the optical density was measured at 550 nm.

Propidium iodide staining and cell cycle analysis

After treatment with 9cRA or EB1089 cells were harvested by trypsinization, washed twice with sample buffer (PBS + 1 g l⁻¹ glucose) and fixed in 70% ethanol at a density of 1 × 10⁶ cells ml⁻¹. After > 18 h the cells were washed with sample buffer and resuspended in propidium iodide (PI) staining solution containing 50 μg ml⁻¹ PI and 20 μg ml⁻¹ RNAase. Fluorescence was measured on a Becton-Dickinson FACScan and DNA histograms were analysed using ModfitLT software.

Apoptosis assays

The Boehringer-Mannheim Cell Death Detection ELISA kit, which detects the presence of histone-associated DNA fragments in the cell cytosol, was used according to the manual supplied by the manufacturer. Results were confirmed using 7-AAD staining followed by flow cytometry, as previously described (Philpott et al, 1996) and PI staining as described above. The three methods were compared and gave very similar results.

Statistical analysis

All statistical comparisons were made using an unpaired, two-tailed t-test; *P < 0.05, **P < 0.01, ***P < 0.005.

RESULTS

Growth inhibition

AsPc-1, BxPc-3 and T3M-4 cells were treated with the test compounds at the indicated concentrations for up to 6 days. Total
and are expressed as means of three determinations. Different cell cycle phases are shown for BxPc-3 and T3M-4 cells on day 2, and 50 nM EB1089, alone or in combination. Percentages of cells in the G1 phase of the cell cycle, as determined by propidium iodide staining and flow cytometric analysis. The concentrations used were 500 nM 9cRA and 50 nM EB1089, alone or in combination. Percentages of cells in the different cell cycle phases are shown for BxPc-3 and T3M-4 cells on day 2, and are expressed as means of three determinations.

![Figure 3](image)

**Figure 3** Growth inhibition was accompanied by an accumulation of cells in the G1 phase of the cell cycle, as determined by propidium iodide staining and flow cytometric analysis. The concentrations used were 500 nM 9cRA and 50 nM EB1089, alone or in combination. Percentages of cell in the different cell cycle phases are shown for BxPc-3 and T3M-4 cells on day 2, and are expressed as means of three determinations.

In two of the cell lines (BxPc-3 and AsPc-1) the combinations were more efficient than 9cRA. In three of the cell lines the combinations were also less potent than 9cRA on its own. This suggests that the retinoic acids and the vitamin D analogues use different mechanisms to achieve the decrease in cell number seen at the end of the treatment period.

While the retinoic acids were shown to induce apoptotic cell death, EB1089 and CB1093 failed to do so. This is an interesting observation as the cells do express VDR (Kawa et al, 1996 and unpublished data) and are clearly responsive to the analogues, which have been shown to induce apoptosis in various other cell types (James et al, 1995, 1998; Danielsson et al, 1997). As previously described for butyrate-induced differentiation in pancreatic tumour lines, cells became enlarged and flattened with filamentous protrusions bridging separate cells, indicating that the cells may be undergoing differentiation (E1-Deriny et al, 1987) (Figure 4).

**Induction of apoptosis**

Following single-agent treatment with 9cRA, EB1089 or CB1093, or co-treatment with 9cRA + EB1089 or 9cRA + CB1093 for 6 days, apoptosis was assessed as described in Materials and Methods. 9cRA alone was shown to induce apoptosis in all three cell lines in a dose-dependent manner, whereas neither of the two vitamin D analogues had this effect, even at the maximal concentration of 50 nM (Figure 5). When EB1089 or CB1093 were added to T3M-4 cells together with 9cRA a significant decrease in apoptotic cell death could be seen (Figure 5B), indicating that the vitamin D analogues block induction of apoptosis by 9cRA. Similar effects were observed in cells co-treated with ATRA + EB1089, such that EB1089 had a clearly negative effect on induction of apoptosis by ATRA (not shown).

T3M-4 cells were subsequently subjected to sequential treatment with 50 nM of EB1089 for three days followed by 500 nM of 9cRA for 6 days. This resulted in complete blockage of apoptosis. In contrast, pretreatment with 9cRA for three days before addition of EB1089 did not make any difference compared to treatment with EB1089 alone (Figure 5C).

Pretreatment with EB1089 for three days also resulted in reduced apoptosis in response to the alkylating agent cisplatin (10 μM for 24 h), showing that the effect was not entirely specific for retinoid-induced apoptosis (Figure 6).

**DISCUSSION**

The cell lines AsPc-1, BxPc-3 and T3M-4 are well-established in vitro models of ductal pancreatic adenocarcinoma, representing malignant cells derived from a primary tumour (BxPc-3), a lymph node metastasis (T3M-4) and ascites (AsPc-1). In all three lines, ATRA, 9cRA, EB1089 and CB1093 caused inhibition of cell growth in vitro. Despite this, co-treatment with 9cRA and a vitamin D analogue resulted in inhibition that was significantly weaker than that induced by EB1089 or CB1093 alone. In two of the cell lines the combinations were also less potent than 9cRA on its own. This suggests that the retinoic acids and the vitamin D compounds use different mechanisms to achieve the decrease in cell number seen at the end of the treatment period.

© 2000 Cancer Research Campaign

British Journal of Cancer (2000) 83(2), 239–245
induction of apoptosis by 9cRA or ATRA. Again, this suggests that the retinoic acids and the vitamin D compounds activate separate mechanistic pathways and that those pathways are antagonistic and competitive.

The potential mechanisms underlying the antagonism seen between 9cRA and the vitamin D analogues are numerous. Clearly, in the case of co-treatment, direct receptor interactions may play a role. In order to bind efficiently to their specific hormone response elements VDR as well as RARs have to form heterodimers with RXRs. RXRs on the other hand bind to DNA as homodimers. This forms the basis for interactions and competition between pathways activated by retinoids and vitamin D compounds.

Pretreatment with EB1089 for 3 days was shown to be enough to completely block induction of apoptosis by 9cRA. Hence, in this period the vitamin D analogue provoke changes in the cell so that it remains resistant to retinoid-induced apoptosis even after the analogue is removed. Importantly, pretreatment with EB1089 also resulted in reduced apoptosis in response to the non-phase-specific drug cisplatin, which indicates that the phenomenon is not specific for apoptosis induced by retinoids, and accordingly effects on RAR/RXR expression or receptor interactions cannot be solely responsible. In agreement with this, assessment of receptor expression levels during different treatments showed no evidence of any regulation that could be responsible for the observed antagonism (not shown). It is therefore likely that regulation by vitamin D analogues of genes whose products are involved in cell differentiation, proliferation and death play the most important role in this resistance. A number of genes are regulated by 1,25D₃ and its analogues, including the cyclin-dependent kinase inhibitors (CDKI) p21WAF1 and p27Kip1 (Liu et al, 1996; Wang et al, 1996; Matsumoto et al, 1998). Both these proteins have been shown to be up-regulated in the pancreatic cancer cell line BxPc-3 after treatment with 1,25D₃ as well as the synthetic analogue 22-oxa-1,25-dihydroxyvitamin D₃ (OCT) (Kawa et al, 1997), implying that this is the mechanism whereby G0/G1 arrest is achieved. p21WAF1 can also protect cells from apoptosis in some systems (Gartel and Tyner, 1999).

It has already been established that different cell types, and even different cell lines of the same type, respond in different ways to retinoids, vitamin D compounds and combinations of the two. Additive and synergistic effects of the two groups of compounds.

Figure 4 T3M-4 cells photographed on day 6. Control cells (A) have just reached confluency whereas cells treated with 9cRA (B) show signs of dying and cells treated with vitamin D analogues (C, D) are strongly growth inhibited and display morphological changes.
are commonly seen, e.g. in breast and prostate cancer cells where both groups induce growth inhibition, G0/G1 arrest and apoptosis (James et al, 1995; Elstner et al, 1999; Koshizuka et al, 1999). Leukaemia cells on the other hand, show a different response pattern. 9cRA as well as vitamin D induce differentiation, and do so in a cooperative manner. Furthermore, it has been observed in HL-60 cells that vitamin D derivatives, although unable to induce apoptosis on their own, can potentiate induction of apoptosis by 9cRA (James et al, 1999). Differential effects have also been shown in melanoma and colon cancer cells (Kane et al, 1996; Danielsson et al, 1999).

In pancreatic cancer cells, responsiveness to both retinoids and vitamin D analogues have been reported previously (Rosewicz et al, 1995; Bold et al, 1996; Kawa et al, 1996; Louvet et al, 1996; Zugmaier et al, 1996; Colston et al, 1997). However, those studies have mainly assessed inhibition of cell growth and apoptosis has not been examined. In only one study were the combined effects of retinoic acid and a vitamin D derivative studied (Zugmaier et al, 1996), and in contrast to our results, EB1089 potentiated the growth inhibitory effects of both ATRA and 9cRA. The reason for this divergent effect, is most likely that the cell lines studied (Capan-1 and -2) are at a different stage of differentiation compared to our cell lines and distinct expression patterns of RARs, RXRs and VDR may account for contrasting responses. Capan-1 and -2 express lower levels of VDR than e.g. BxPc-3 and are significantly less sensitive to 1,25D3 than this cell line (Kawa et al, 1996). RAR-α and γ are expressed in our cell lines as well as Capan-1 and -2, but no or low levels of RAR-β are generally detected (Rosewicz et al, 1995; Kaiser et al, 1998 and our observations).

Figure 5 Assessment of apoptosis by Cell Death Detection ELISA, detecting the presence of histone-associated DNA fragments in the cell cytosol. The enrichment factor is calculated as OD (treated cells)/OD (untreated cells). (A) 9cRA, but neither EB1089 nor CB1093 induced apoptosis in the three cell lines. (B) Combinations of 9cRA with EB1089 or CB1089 resulted in very weak induction of apoptosis in T3M-4 cells compared to treatment with 9cRA alone, and (C) preincubation with EB1089 for 3 days completely blocked induction of apoptosis by 9cRA. The concentrations used were 500 nM of 9cRA and 50 nM of the vitamin D analogues. Statistical comparisons were made of control vs treated cells (A) and 9cRA vs 9cRA + EB1089 or CB1093 (B).
The Bcl-2 family of proteins regulates responses to a variety of apoptotic stimuli, and includes anti-apoptotic (Bcl-2, Bcl-XL, McI-1 and A1) as well as pro-apoptotic members (Bax, Bcl-Xs, etc.) (Korsmeyer, 1999). For example, in breast cancer cells which undergo apoptosis in response to vitamin D compounds, down-regulation of the anti-apoptotic protein Bcl-2 and an increased Bax/Bcl-2 ratio can be observed (James et al., 1998). This is also observed in HL-60 leukaemia cells, and is thought to be a mechanism whereby vitamin D derivatives potentiate induction of apoptosis by 9cRA (James et al., 1999). However, 1,25D3 has also been reported to have an anti-apoptotic effect in HL-60 cells, and this was associated with induction of differentiation and up-regulation of McI-1 (Wang and Studzinski, 1997). We are currently investigating the effects of EB1089, CB1093 and 9cRA on expression of these pro- and anti-apoptotic proteins in pancreatic cancer cells, to assess their role in the differential effects observed.

The conclusions that can be drawn from this study are that both retinoids and vitamin D analogues may have a role to play in management of pancreatic cancer, but the outcome of the two treatments will be different. Vitamin D analogues can slow down cell growth but do not kill the cells, whereas retinoids do both. It also points out that the two groups of compounds should probably not be used together as they counteract each other in vitro.

**ACKNOWLEDGEMENTS**

This work was supported by The Ralph Bates Pancreatic Research Fund.

**REFERENCES**

Bold RJ, Ishizuka J, Townsend CMJ and Thompson JC (1996) All-trans-retinoic acid inhibits growth of human pancreatic cancer cell lines. *Pancreas* **12**: 189–195

Bollag W, Majewski S and Jablonska S (1994) Cancer combination chemotherapy with retinoids: experimental rationale. *Leukemia* **8**: 1453–1457

Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante T, Sanders WH, Berjian R, Douglass HO, Martin EW and Ming Chu T (1982) Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. *In vitro* **18**: 24–34

Colston KW (1997) Vitamin D and breast cancer: therapeutic potential of new vitamin D analogues. In: *Vitamin D*, Feldman D (ed), pp. 1107–1123. Academic Press, San Diego

Colston KW, James SJ, Ofori-Kuragu EA, Binderup L and Grant AG (1997) Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. *Br J Cancer* 76: 1017

Danielsson C, Mathiasen IS, James SJ, Nayeri S, Breetting C, Hansen CM, Colston KW and Carlberg C (1997) Sensitive induction of apoptosis in breast cancer cells by a novel 1,25-dihydroxyvitamin D3 analogue shows relation to promoter selectivity. *J Cell Biochem* **66**: 552–562

![Figure 6](image-url) Propidium iodide staining and flow cytometric analysis of T3M-4 and BxPc-3 cells showed that pretreatment with EB1089 for 3 days before addition of cisplatin (10 μM) for 24 h reduced the percentage of cells with sub-G1 DNA content. Percentages shown are means of two determinations. The total number of cells being analysed varies between the samples, as cell fragments and aggregates of two or more cells had to be excluded.
Korsmeyer SJ (1999) BCL-2 gene family and the regulation of programmed cell death. *Cancer Res* 59: 1693s–1700s

Koshizuka K, Kubota T, Saito J, Koike M, Binderup L, Uskokovic M and Koeffler HP (1999) Combination therapy of a vitamin D analog and all-trans-retinoic acid: effect on human breast cancer in nude mice. *Anticancer Res* 19: 519–524

Levin AA, Sturzenbecker LJ, Kazmer S, Bosakovskiy T, Huselton C, Allenby G, Speck G, Kretzsen C, Rosenberger M, Lovey and A Grippio FJ (1992) 9-cis retinoid acid stereosomers binds and activates the nuclear receptor RXRα. *Nature* 355: 359–361

Li M, Lee M-H, Cohen M, Bommakanti M and Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D leads to the induced differentiation of the myelomonocytic cell line U937. *Genes Dev* 10: 142–153

Lottin R (1996) Retinoids in cancer chemoprevention. *Faseb J* 10: 1031–1039

Louvet C, Djelloul S, Forgue-Lafitte ME, Mester J, Zamber A and Gespach C (1996) Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alfa. *Br J Cancer* 74: 394–399

Mathiasen IS, Colston KW and Binderup L (1993) EB1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. *J Steroid Biochem Mol Biol* 46: 365–371

Matsumoto T, Sowa Y, Ohtani-Fujita N, Tamaki T, Takenaka T, Kuribayashi K and Sakai T (1998) p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. *Cancer Lett* 129: 61–68

Nagy L, Thomazy VA, Heyman RA and Davies PG (1996) Retinoid-induced apoptosis in normal and neoplastic tissues. *Cell Death Differ* 3: 11–19

Okabe T, Yamaguchi N and Oshawa N (1983) Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. *Cancer* 51: 662–668

Petkovich M, Brand NJ, Krust A and Chambon P (1987) A human retinoid acid receptor which belongs to the family of nuclear receptors. *Nature* 330: 444–450

Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, Dalgleish AG and Gibson AG (1996) The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. *Blood* 87: 2244–2251

Rosewicz S and Wiedenmann B (1997) Pancreatic carcinoma. *Cancer* 349: 485–489

Rosewicz S, Stier U, Brembeck F, Wiedenmann B and Riecken EO (1995) Retinoids: effect on growth, differentiation and nuclear receptor expression in human pancreatic carcinoma cell lines. *Gastroenterology* 109: 1646–1660

Rothenberg ML, Moore MJ, Cripps MC, Andersen, Portenoy RK, Burris HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Stornioli AM and Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer. *Ann Oncol* 7: 247–253

Sokhan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst* 82: 1107–1112

Tan MH, Nowak NJ, Loo R, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian, R, Douglass HD and Chu TM (1986) Characterization of a new primary human pancreatic tumour line. *Cancer Invest* 4: 15–23

Wang QM, Jones JB and Studzinski GP (1996) Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. *Cancer Res* 56: 264–267

Wang X and Studzinski GP (1997) Antiproliferative action of 1,25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAP-1 proteins and reduced release of cytochrome c. *Exp Cell Res* 235: 210–217

Zagzaga G, Jager R, Grage B, Gottardis MM, Havemann K and Knabbe C (1996) Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. *Br J Cancer* 73: 1341–1346

© 2000 Cancer Research Campaign

British Journal of Cancer (2000) 83(2), 239–245